Krilogy Financial’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Krilogy Financial’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10	Closed	–	–	787
2018 Q3	$0	Buy	+10	New	+$257	﹤0.01%	849

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Krilogy Financial's AVEO Position: Q4 2018 in Review

Krilogy Financial sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 10 shares.

Krilogy Financial first reported a position in AVEO in Q3 2018 and held it in 1 quarter. The position peaked at $0 in Q3 2018. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

Krilogy Financial reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Krilogy Financial sold 10 AVEO Pharmaceuticals, Inc. shares in Q4 2018.
Krilogy Financial first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2018 and held it in 1 quarter.
Krilogy Financial's AVEO Pharmaceuticals, Inc. position peaked at $0 in Q3 2018.
99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.